# A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07285148/  
OnCo record `nct07285148` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of osimertinib in lung cancer, run by Beijing Pearl Biotechnology Limited Liability Company, not yet recruiting.

## Summary

A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer is a phase 1/2, randomised interventional study registered as NCT07285148 by Beijing Pearl Biotechnology Limited Liability Company, with a registry enrolment figure of 253 participants, started 2026-06 and due to reach its primary completion in 2029-12. Interventions recorded: ANS014004 + PLB1004; ANS014004 + Osimertinib. Conditions listed: Non-Small Cell Lung Cancer; EGFR Mutation; Metastatic Lung Cancer; MET Alteration. Primary outcome: Number of participants with dose-limiting toxicity (DLT) during the DLT observation period (Phase Ib Dose Escalation); Maximum tolerated dose (MTD) of ANS014004 in combination with PLB1004 (Phase Ib Dose Escalation); Objective Response Rate (ORR) assessed by investigator per RECIST v1.1 (Phase Ib Do. Lung eligibility wording from the registry: "Patients with histologically or cytologically confirmed diagnosis of unresectable locally advanced (Stage IIIB and IIIC) or metastatic (Stage IV) NSCLC (according to the lung cancer staging criteria, refer to the eighth edition of the American Joint Committee on Cancer \[AJCC\] Lung Cancer Staging)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07285148
- Phase: 1/2
- Setting: An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of ANS014004 in Combination With EGFR-TKI in Patients With EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Sponsor: Beijing Pearl Biotechnology Limited Liability Company
- Enrolled: 253

## Sources

- ClinicalTrials.gov NCT07285148: https://clinicaltrials.gov/study/NCT07285148

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Osimertinib](https://onco.cc/drugs/osimertinib/)
- companies: [Avistone Biotechnology](https://onco.cc/companies/avistone-biotechnology/), [Beijing Pearl Biotechnology Limited Liability Company](https://onco.cc/companies/beijing-pearl-biotechnology-limited-liability-company/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07285148.json